Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with submicromolar inhibitory concentrations (IC₅₀ ROCK1: 140 nM; Ki ROCK2: 300 nM) [product]. The compound exhibits over 200-fold selectivity for ROCK kinases versus related kinases such as PKC and MLCK, minimizing off-target effects [DOI]. Y-27632 has been validated in studies on cytoskeletal remodeling, inhibition of Rho-mediated stress fiber formation, and suppression of tumor invasion and metastasis in vivo. It enhances stem cell viability and supports cell proliferation assays across diverse model systems. Stringent solubility and storage guidelines ensure experimental reproducibility [product].

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are central effectors in the Rho GTPase signaling pathway. These kinases regulate actin cytoskeleton reorganization, cell shape, motility, and proliferation. Inhibition of ROCK activity disrupts the Rho-mediated assembly of stress fibers and focal adhesions, affecting cell contractility and migration [DOI]. Aberrant Rho/ROCK signaling is implicated in pathological processes such as fibrosis, tumor invasion, stem cell senescence, and impaired tissue regeneration. Selective ROCK inhibitors like Y-27632 enable researchers to precisely modulate this pathway, offering mechanistic insight into cytoskeletal dynamics and disease progression. For a strategic overview, see Redefining Translational Research: Leveraging Y-27632 Dihydrochloride, which reviews the translational implications; this article extends that work by providing detailed experimental parameters and benchmark data.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride acts as a reversible, ATP-competitive inhibitor targeting the catalytic domains of ROCK1 and ROCK2. The compound binds with high affinity (IC₅₀ for ROCK1: ~140 nM; Ki for ROCK2: 300 nM) and displays over 200-fold selectivity against kinases such as PKC, cAMP-dependent protein kinase, MLCK, and PAK [DOI]. This selectivity profile ensures minimal inhibition of unrelated signaling pathways. Upon ROCK inhibition, Rho-mediated phosphorylation of downstream effectors such as myosin light chain (MLC) is blocked, leading to disassembly of actin stress fibers and perturbation of cell contractility. Y-27632 thereby modulates G1-S cell cycle progression and interferes with cytokinesis. For a mechanistic analysis of how Y-27632 disrupts stress fiber formation and cell cycle, see Y-27632 Dihydrochloride: Precision ROCK Inhibition for Stem Cell Research; this present article further clarifies in vivo benchmarks and solubility protocols.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a Ki of 300 nM, demonstrating high potency in cell-free kinase assays (https://www.apexbt.com/y-27632-dihydrochloride.html).
• The compound shows >200-fold selectivity for ROCK1/2 over PKC, cAMP-dependent protein kinase, MLCK, and PAK in in vitro kinase panels (https://doi.org/10.1016/j.jcf.2022.02.011).
• Y-27632 at 10 μM inhibits Rho-mediated stress fiber formation and focal adhesion assembly in fibroblasts within 30 min, as observed by phalloidin/F-actin staining (https://doi.org/10.1016/j.jcf.2022.02.011).
• In primary prostatic smooth muscle cells, Y-27632 reduces proliferation rate by >50% in a concentration-dependent manner, assayed after 48 h in vitro (https://www.apexbt.com/y-27632-dihydrochloride.html).
• In vivo, administration of Y-27632 (20 mg/kg IP) in mouse tumor models leads to a significant decrease in tumor invasion and metastatic foci after two weeks (https://doi.org/10.1016/j.jcf.2022.02.011).
• Solubility benchmarks: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at 25°C. Solubility increases with warming or sonication (https://www.apexbt.com/y-27632-dihydrochloride.html).
• Stock solutions at 10 mM in DMSO remain stable for several months at <-20°C, but long-term storage of working solutions is not recommended (https://www.apexbt.com/y-27632-dihydrochloride.html).

Applications, Limits & Misconceptions

Applications

• Cytoskeletal Studies: Y-27632 is routinely used to dissect Rho/ROCK-mediated actin reorganization and cell motility (https://doi.org/10.1016/j.jcf.2022.02.011).
• Stem Cell Viability and Expansion: The compound enhances survival of dissociated human pluripotent stem cells and supports organoid formation, as reviewed in Y-27632 dihydrochloride: Selective ROCK1/2 Inhibition for Stem Cell Research; this article updates those protocols with new in vivo benchmarks.
• Tumor Invasion and Metastasis: In vivo, Y-27632 suppresses pathological structures and tumor cell invasion, providing a preclinical model for anti-metastatic strategies (https://doi.org/10.1016/j.jcf.2022.02.011).
• Cell Proliferation and Cytokinesis Studies: The product is used to interrogate cell cycle transitions and cytokinesis blockade.

Common Pitfalls or Misconceptions

• Y-27632 is not an effective inhibitor of non-ROCK kinases such as PKC or MLCK at standard working concentrations (<10 μM).
• Long-term exposure (>72 h) in culture may induce compensatory signaling or toxicity in some sensitive cell types.
• It does not reverse pre-existing cytoskeletal defects caused by genetic mutations outside the Rho/ROCK pathway.
• Y-27632 is not suitable as an in vivo systemic therapy due to rapid clearance and off-target pharmacodynamics at high doses.
• Solubility issues arise if the compound is not fully dissolved (warming or using an ultrasonic bath is recommended).

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be stored desiccated at 4°C or lower. For working solutions, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Use warming to 37°C or an ultrasonic bath to maximize solubility. Prepare aliquots to avoid repeated freeze-thaw cycles; store stock solutions at <-20°C. For in vitro use, typical concentrations range from 1–50 μM, with 10 μM being standard for cytoskeletal assays. For in vivo models, consult recent literature for dosing schedules, as pharmacokinetics may vary by species and administration route. For advanced protocol guidance, see Y-27632 Dihydrochloride: Selective ROCK Inhibition for Pluripotency Continuum Research; this article clarifies solubility and storage best practices for reproducibility.

Conclusion & Outlook

Y-27632 dihydrochloride is a robust, selective ROCK1/2 inhibitor with validated applications in cytoskeletal, stem cell, and tumor invasion research. Its defined kinetic, solubility, and selectivity profiles enable reproducible experimental outcomes. As understanding of Rho/ROCK signaling evolves, Y-27632 remains essential for dissecting pathway-specific effects and modeling disease processes. Researchers should adhere to strict solubility, storage, and dosing guidelines to maximize reproducibility and interpretability of results. For product ordering and specifications, see the A3008 kit.